Cancer, a word that strikes a chord of fear in many, is a fighting word. At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry, and while it is a match we have yet to win, researchers and scientists have on their boxing gloves and are staying in the fight.
ADVENTRX Pharmaceuticals Provides Update on ANX-514
ADVENTRX Pharmaceuticals, Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates principally for the treatment of cancer, recently provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel.
Seno Medical Uses Laser-Based Technology For Early cancer Diagnosis
Seno Medical is a company focused on cancer using its new patented opto-acoustic technology. This new imaging modality combines the use of light in and sound out to uniquely obtain the hallmark […]
T-Ray Science Announces Name Change
T-Ray Science, Inc., a medical device company committed to commercializing innovative systems for the early detection of cancer announces that shareholders approved a change of the name of the Company to Verisante Technology, Inc.
Hunting Disease In The Dark: MEDomics Seeks to Treat Mitochondrial Disease Before It Occurs
The core theory behind preventative medicine is almost psychic. To stop a disease from wielding its mighty weapons before it occurs is based on foreknowledge of a patient’s susceptibility to the illness.
ADVENTRX Pharmaceuticals Takes the Next Step In Approval of ANX-530
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
Oncology Panel Selected in OneMedForum SF 2011
Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer.
NYSSA Announces Presenter List for Upcoming Biotech Conference
The New York Society of Security Analysts, a leading forum for the investment community, recently announced the presenter list for its 14th Annual Biotech and Specialty Pharma Conference.
